FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

The new test has been devised by scientists to detect the likelihood of cancer reoccurring in patients with a type of breast ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Olivia Munn shares how a risk assessment test led to her mom’s early HER2 breast cancer diagnosis Read ahead to know why risk ...

The new test has been devised to detect the likelihood of cancer reoccurring in patients with a type of breast cancer known ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...